The Globe and Mail reports in its Friday, Nov. 8, edition that Stifel analyst Martin Landry continues to rate Kits Eyecare "buy." The Globe's David Leeder writes that Mr. Landry has bumped his Kits Eyecare share target ahead to $15 from $14. Analysts on average target the shares at $15.50. Mr. Landry says in a note: "Kits Eyecare reported strong Q3/24 results, which were in-line with the previously prereleased numbers communicated on Oct. 3. More importantly, the company introduced an impressive Q4/24 financial guidance calling for revenue to growth 36 to 42 per cent year-over-year, and EBITDA margins of 3 to 5 per cent. Q4/24 revenue guidance of $43-million to $45-million was higher than our expectations and consensus of $40-million. Kits Eyecare continues to rapidly gain market share adding new customers and up-selling higher-priced products to its existing customers. New product introductions, successful marketing and new partnerships with insurance providers contributed to the company's recent successes. As a result we have increased our forecasts for Q4/24 and 2025 to reflect recent sales momentum." The Globe reported on April 12 that Mr. Landry continued to rate Kits Eyeware "buy." It was then worth $6.41.